| Product Code: ETC12629502 | Publication Date: Apr 2025 | Updated Date: Feb 2026 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
In 2024, Austria`s large molecules drug substance CDMO market saw a notable increase in imports. This trend reflected a growing reliance on foreign sources for drug substance manufacturing, potentially driven by cost efficiencies or capacity constraints in the domestic market.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Austria Large Molecules Drug Substance CDMO Market Overview |
3.1 Austria Country Macro Economic Indicators |
3.2 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, 2022 & 2032F |
3.3 Austria Large Molecules Drug Substance CDMO Market - Industry Life Cycle |
3.4 Austria Large Molecules Drug Substance CDMO Market - Porter's Five Forces |
3.5 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Service Type, 2022 & 2032F |
3.6 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Molecule Type, 2022 & 2032F |
3.7 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Stage, 2022 & 2032F |
3.8 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Application, 2022 & 2032F |
3.9 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By End User, 2022 & 2032F |
4 Austria Large Molecules Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for biologics and biosimilars in the pharmaceutical industry. |
4.2.2 Growing trend of outsourcing drug substance manufacturing to CDMOs due to cost efficiencies and expertise. |
4.2.3 Advancements in technology and manufacturing processes leading to increased complexity and scale of large molecule drug substances. |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements and quality standards for large molecule drug substance manufacturing. |
4.3.2 Pricing pressures and competition within the CDMO market. |
4.3.3 Potential supply chain disruptions and global trade uncertainties affecting the market. |
5 Austria Large Molecules Drug Substance CDMO Market Trends |
6 Austria Large Molecules Drug Substance CDMO Market, By Types |
6.1 Austria Large Molecules Drug Substance CDMO Market, By Service Type |
6.1.1 Overview and Analysis |
6.1.2 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Service Type, 2022 - 2032F |
6.1.3 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Process Development, 2022 - 2032F |
6.1.4 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Manufacturing, 2022 - 2032F |
6.1.5 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Analytical Services, 2022 - 2032F |
6.1.6 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Regulatory Support, 2022 - 2032F |
6.1.7 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Packaging, 2022 - 2032F |
6.2 Austria Large Molecules Drug Substance CDMO Market, By Molecule Type |
6.2.1 Overview and Analysis |
6.2.2 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Monoclonal Antibodies, 2022 - 2032F |
6.2.3 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Recombinant Proteins, 2022 - 2032F |
6.2.4 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Peptides, 2022 - 2032F |
6.2.5 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Nucleic Acids, 2022 - 2032F |
6.2.6 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Viral Vectors, 2022 - 2032F |
6.3 Austria Large Molecules Drug Substance CDMO Market, By Stage |
6.3.1 Overview and Analysis |
6.3.2 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Preclinical, 2022 - 2032F |
6.3.3 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Clinical, 2022 - 2032F |
6.3.4 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Commercial, 2022 - 2032F |
6.3.5 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Late-Stage, 2022 - 2032F |
6.3.6 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Early-Stage, 2022 - 2032F |
6.4 Austria Large Molecules Drug Substance CDMO Market, By Application |
6.4.1 Overview and Analysis |
6.4.2 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Oncology, 2022 - 2032F |
6.4.3 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Immunology, 2022 - 2032F |
6.4.4 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Neurology, 2022 - 2032F |
6.4.5 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Rare Diseases, 2022 - 2032F |
6.4.6 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Infectious Diseases, 2022 - 2032F |
6.5 Austria Large Molecules Drug Substance CDMO Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Pharmaceutical Companies, 2022 - 2032F |
6.5.3 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Biopharmaceutical Companies, 2022 - 2032F |
6.5.4 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By Research Institutes, 2022 - 2032F |
6.5.5 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By CROs, 2022 - 2032F |
6.5.6 Austria Large Molecules Drug Substance CDMO Market Revenues & Volume, By CMOs, 2022 - 2032F |
7 Austria Large Molecules Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 Austria Large Molecules Drug Substance CDMO Market Export to Major Countries |
7.2 Austria Large Molecules Drug Substance CDMO Market Imports from Major Countries |
8 Austria Large Molecules Drug Substance CDMO Market Key Performance Indicators |
8.1 Percentage of repeat business from existing clients, indicating customer satisfaction and loyalty. |
8.2 Average lead time for manufacturing large molecule drug substances, reflecting operational efficiency and responsiveness. |
8.3 Number of successful technology transfers and new product introductions, showcasing innovation and capabilities. |
8.4 Percentage of revenue from emerging markets, demonstrating market diversification and growth potential. |
8.5 Employee training hours invested in new technologies and processes, highlighting continuous improvement and expertise development. |
9 Austria Large Molecules Drug Substance CDMO Market - Opportunity Assessment |
9.1 Austria Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Service Type, 2022 & 2032F |
9.2 Austria Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Molecule Type, 2022 & 2032F |
9.3 Austria Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Stage, 2022 & 2032F |
9.4 Austria Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Application, 2022 & 2032F |
9.5 Austria Large Molecules Drug Substance CDMO Market Opportunity Assessment, By End User, 2022 & 2032F |
10 Austria Large Molecules Drug Substance CDMO Market - Competitive Landscape |
10.1 Austria Large Molecules Drug Substance CDMO Market Revenue Share, By Companies, 2025 |
10.2 Austria Large Molecules Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here